WO2000021980A1 - Utilisation de desintegrines synthetiques mimetiques arg-gly-asp (rgd) incorporees dans un chelateur comme agents d'imagerie - Google Patents

Utilisation de desintegrines synthetiques mimetiques arg-gly-asp (rgd) incorporees dans un chelateur comme agents d'imagerie Download PDF

Info

Publication number
WO2000021980A1
WO2000021980A1 PCT/US1999/023511 US9923511W WO0021980A1 WO 2000021980 A1 WO2000021980 A1 WO 2000021980A1 US 9923511 W US9923511 W US 9923511W WO 0021980 A1 WO0021980 A1 WO 0021980A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound according
formula
acid
compounds
kit
Prior art date
Application number
PCT/US1999/023511
Other languages
English (en)
Inventor
Milind Rajopadhye
Prahland R. Singh
Original Assignee
Du Pont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharmaceuticals Company filed Critical Du Pont Pharmaceuticals Company
Priority to CA002341672A priority Critical patent/CA2341672A1/fr
Priority to JP2000575885A priority patent/JP2002527450A/ja
Priority to AU64222/99A priority patent/AU6422299A/en
Priority to EP99951874A priority patent/EP1121377A1/fr
Publication of WO2000021980A1 publication Critical patent/WO2000021980A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Definitions

  • This invention relates to novel radiopharmaceuticals that are radiolabeled chelator incorporated RGD mimetic synthetic disintegrins, methods of using the same as imaging agents for the diagnosis of arterial and venous thrombi, and novel reagents for the preparation of the same and kits comprising the reagents.
  • Platelet activation and aggregation is also thought to play a significant role in venous thromboembolic disorders such as venous thrombophlebitis and subsequent pulmonary emboli. It is also known that patients whose blood flows over artificial surfaces, such as prosthetic synthetic cardiac valves, are at risk for the development of platelet plugs, thrombi and emboli. See generally Fuster et al . , J. Am. Coll. Cardiol., Vol. 5, No. 6, pp. 175B-183B (1985); Rubenstein et al . , Am. Heart J. , Vol. 102, pp. 363-367 (1981); Hamm et al . , J. Am. Coll. Cardiol., Vol. 10, pp. 998-1006 (1987); and Davies et al . , Circulation, Vol. 73, pp. 418-427 (1986) .
  • one object of the present invention is to provide novel compounds for making radiopharmaceuticals which act as antagonists of the platelet glycoprotein Ilb/IIIa complex.
  • the present invention provides a novel compound of formula (I) :
  • R 1 is selected from the group H and NH 2 ;
  • R 2 is selected from the group CH 2 C0 2 H and CH 2 CH 2 C0 2 H;
  • R 3 is selected from the group:
  • n 0 or 1.
  • the present invention provides a novel compound wherein;
  • the present invention provides a novel compound wherein;
  • R 1 is NH 2 ;
  • R 2 is CH 2 C0 2 H
  • n 0.
  • the present invention provides a novel compound wherein;
  • R 1 is H
  • R 2 is CH 2 C0 2 H
  • n 0.
  • the present invention provides a novel compound wherein;
  • R 1 is NH 2 ;
  • R 2 is CH 2 C0 2 H
  • n 1.
  • the present invention provides a novel compound wherein; R 1 is NH 2 ;
  • R 2 is CH C0 2 H
  • n 0.
  • the present invention provides a novel compound wherein;
  • R 1 is H ;
  • R 2 is CH 2 C0 2 H ;
  • n 0.
  • the present invention provides a novel kit for preparing a radiopharmaceutical comprising a predetermined quantity of a compound of formula (I) or a pharmaceutically acceptable salt form thereof.
  • the present invention provides a novel radiopharmaceutical comprising a complex of a compound of formula (I) and 99 m Tc.
  • the present invention provides a novel radiopharmaceutical composition
  • a radiopharmaceutically acceptable carrier and a 99 ⁇ r ⁇ Tc labeled compound of formula (I) .
  • the present invention provides a novel method of imaging, comprising:
  • the method of imaging is for visualizing sites of platelet deposition in a mammal.
  • the method of imaging is for determining platelet deposition in a mammal.
  • the method of imaging is for diagnosing a disorder associated with platelet deposition in a mammal.
  • the present invention provides a novel sterile, non-pyrogenic kit for radioimaging a mammal, comprising: (a) a predetermined quantity of a compound of formula (I) ; and,
  • components (a) and (b) are contained in a vial.
  • component (a) is contained in a first vial and component (b) is contained in a second vial.
  • the reducing agent is stannous chloride.
  • the compounds of the present invention may be radiolabeled.
  • radiolabeled it is meant that the subject platelet glycoprotein Ilb/IIIa compounds contain a radioisotope which is suitable for administration to a mammalian patient
  • metal chelator and “chelator” are used interchangeably throughout to designate a chemical moiety capable of binding to or complexing with a metal nuclide.
  • the platelet glycoprotein Ilb/IIIa compounds of the present invention may be radiolabeled by incorporating the radiolabel into the compounds through a chelating agent, where the chelating agent has been incorporated into the compounds.
  • the metal chelator is intended to be the group:
  • the radiolabeled compounds of the invention may be useful as radiopharmaceuticals for non-invasive imaging to diagnose present or potential thromboembolic disorders, such as arterial or venous thrombosis, including, for example, unstable angina, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, diabetes, thrombophlebitis, pulmonary emboli, platelet plugs, and thrombi or emboli caused by prosthetic cardiac devices such as heart valves .
  • the radiolabeled compounds of the invention may be useful with both newly formed and older thrombi .
  • the radiolabeled compounds of the invention may also be used to diagnose other present or potential conditions where there is overexpression of the GPIIb/IIIa receptors, such as with metastatic cancer cells.
  • the subject compounds may be effectively employed in low doses, thereby minimizing any risk of toxicity.
  • the subject compounds are of a much smaller size than, for example, the radiolabeled 7E3 antibodies known in the art, allowing easier attainment of suitable target/background (T/B) ratio for detecting thrombi.
  • T/B target/background
  • a “diagnostic kit,” as used herein, comprises a collection of components, termed the formulation, in one or more vials which are used by the practising end user in a clinical or pharmacy setting to synthesize the radiopharmaceutical.
  • the kit provides all the requisite components to synthesize and use the radiopharmaceutical except those that are commonly available to the practising end user, such as water or saline for injection, a solution of the radionuclide, equipment for heating the kit during the synthesis of the radiopharmaceutical if required, equipment necessary for administering the radiopharmaceutical to the patient such as syringes and shielding, and imaging equipment.
  • kits may be contained in one or more vials and all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid. It is preferred that reagent and reducing agent be lyophilized, when possible, to facilitate storage stability. If lyophilization is not practical, the kits can be stored frozen or in solution at room temperature.
  • the solvents used are usually water or saline, preferably, water. Preferably, the kits are sealed.
  • a “buffer, " as used herein, is a compound that is used to control the pH of the kit during its manufacture and during the synthesis of the radiopharmaceutical.
  • a “lyophilization aid, " as used herein, is a component that has favorable physical properties for lyophilization, such as the glass transition temperature, and is added to the diagnostic kit to improve the physical properties of the combination of all the components of the kit for lyophilization .
  • a “stabilization aid,” as used herein, is a component that is added to the radiopharmaceutical or to the diagnostic kit either to stabilize the radiopharmaceutical once it is synthesized or to prolong the shelf-life of the kit before it must be used.
  • Stabilization aids can be antioxidants, reducing agents or radical scavengers and can provide improved stability by reacting preferentially with species that degrade other components or the radiopharmaceutical .
  • a “solubilization aid,” as used herein, is a component that improves the solubility of one or more other components in the medium required for the synthesis of the radiopharmaceutical.
  • a “bacteriostat, " as used herein, is a component that inhibits the growth of bacteria in the diagnostic kit either during its storage before use of after the kit is used to synthesize the radiopharmaceutical.
  • a “reducing agent, " as used herein, is a compound that reacts with the radionuclide, which is typically obtained as a relatively unreactive, high oxidation state compound, to lower its oxidation state by transfering electron (s) to the radionuclide, thereby making it more reactive.
  • Reducing agents useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to stannous chloride, stannous fluoride, formamidine sulfinic acid, ascorbic acid, cysteine, phosphines, and cuprous or ferrous salts. Other reducing agents are described in Brodack et. al . , PCT Application 94/22496, which is incorporated herein by reference.
  • a "transfer ligand, " as used herein, is a ligand that forms an intermediate complex with the radionuclide that is stable enough to prevent unwanted side-reactions but labile enough to be converted to the radiopharmaceutical .
  • the formation of the intermediate complex is kinetically favored while the formation of the radiopharmaceutical is thermodynamically favored.
  • Transfer ligands useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to gluconate, glucoheptonate, mannitol, glucarate, N,N, N' ,N' -ethylenediaminetetraacetic acid, pyrophosphate and methylenediphosphonate .
  • transfer ligands are comprised of oxygen or nitrogen donor atoms .
  • Pg is selected from a variety of thiol protecting groups capable of being displaced upon reaction with a radionuclide, or deprotected under the reaction (radiolabeling) conditions.
  • thiol protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis” John Wiley & Sons, New York (1991) , the disclosure of which is hereby incorporated by reference. Any thiol protecting group known by those skilled in the art can be used.
  • thiol protecting groups include the following: acetamidomethyl (ACM) , 1-ethoxyethyl (EOE) , p-anisylidene, tetrahydropyranyl (THP) , tetrahydrofuranyl (THF) , and derivatives thereof.
  • amine protecting group means any group known in the art of organic synthesis for the protection of amine groups .
  • Such amine protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis” John Wiley & Sons, New York (1991) and “The Peptides: Analysis, Sythesis, Biology, Vol. 3, Academic Press, New York (1981) , the disclosure of which is hereby incorporated by reference. Any amine protecting group known in the art can be used.
  • amine protecting groups include, but are not limited to, the following: 1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyls , 1- (p-biphenyl ) -1-methylethoxycarbonyl , and 9-fluorenylmethyloxycarbonyl (Fmoc) ; 3) aliphatic carbamate types such as tert-butyloxycarbonyl (Boc) , ethoxycarbonyl , diisopropylmethoxycarbonyl , and allyloxycarbonyl; 4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl ; 5) alkyl types such as triphenylmethyl and benzyl
  • acyl groups such as azidobenzoyl, p-benzoylbenzoyl, o-benzylbenzoyl, p- acetylbenzoyl, dansyl, glycyl-p-benzoylbenzoyl, phenylbenzoyl, m-benzoylbenzoyl , benzoylbenzoyl .
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; and alkali or organic salts of acidic residues such as carboxylic acids.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non- toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pa oic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference .
  • prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc..) the compounds of the present invention may be delivered in prodrug form.
  • the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same.
  • Prodrugs are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl , free amino, or free sulfhydryl group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.
  • amino acid as used herein means an organic compound containing both a basic amino group and an acidic carboxyl group. Included within this term are modified and unusual amino acids, such as those disclosed in, for example, Roberts and Vellaccio (1983) The Peptides, 5: 342- 429, the teaching of which is hereby incorporated by reference.
  • Modified or unusual amino acids which can be used to practice the invention include, but are not limited to, D-amino acids, hydroxylysine, 4-hydroxyproline, ornithine, 2 , 4-diaminobutyric acid, 2 , 3-diaminopropionic acid, beta-2-thienylalanine, 4-aminophenylalanine, homoarginine , norleucine, N-methylaminobutyric acid, naphthylalanine, phenylglycine, ⁇ -phenylproline, tert-leucine, 4-aminocyclohexylalanine, N-methyl-norleucine, 3 , 4-dehydroproline, 4-aminopiperidine-4-carboxylic acid, 6- aminocaproic acid, trans-4- (aminomethyl) - cyclohexanecarboxylic acid, 2-, 3-, and 4- (aminomethyl) - benzoic acid, 1-aminocyclopentan
  • amino acid residue means that portion of an amino acid (as defined herein) that is present in a peptide.
  • peptide as used herein means a linear compound that consists of two or more amino acids (as defined herein) that are linked by means of a peptide bond.
  • peptide also includes compounds containing both peptide and non-peptide components , such as pseudopeptide or peptide mimetic residues or other non-amino acid components. Such a compound containing both peptide and non-peptide components may also be referred to as a "peptide analog" .
  • TFMSA trifluoromethane sulfonic acid
  • peptides are elongated by deprotecting the ⁇ -amine of the C-terminal residue and coupling the next suitably protected amino acid through a peptide linkage using the methods described. This deprotection and coupling procedure is repeated until the desired sequence is obtained.
  • This coupling can be performed with the constituent amino acids in a stepwise fashion, or condensation of fragments (two to several amino acids) , or combination of both processes, or by solid phase peptide synthesis according to the method originally described by Merrifield, J. Am. Chem. Soc . , 85, 2149-2154 (1963), the disclosure of which is hereby incorporated by reference.
  • the compounds of the invention may also be synthesized using automated peptide synthesizing equipment.
  • procedures for peptide synthesis are described in Stewart and Young, "Solid Phase Peptide Synthesis", 2nd ed, Pierce Chemical Co., Rockford, IL (1984); Gross, Meienhofer, Udenfriend, Eds., "The Peptides : Analysis, Synthesis, Biology, Vol. 1, 2, 3, 5, and 9,
  • the coupling between two amino acid derivatives, an amino acid and a peptide, two peptide fragments, or the cyclization of a peptide can be carried out using standard coupling procedures such as the azide method, mixed carbonic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimides) method, active ester (p- nitrophenyl ester, N-hydroxysuccinic imido ester) method, Woodward reagent K method, carbonyldiimidazole method, phosphorus reagents such as BOP-Cl, or oxidation-reduction method.
  • standard coupling procedures such as the azide method, mixed carbonic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or
  • These protecting groups include: 1) alkyl esters such as methyl and t-butyl, 2) aryl esters such as benzyl and substituted benzyl, or 3) esters which can be cleaved by mild base treatment or mild reductive means such as trichloroethyl and phenacyl esters .
  • the C-terminal amino acid is attached to an insoluble carrier (usually polystyrene) .
  • insoluble carriers contain a group which will react with the carboxyl group to form a bond which is stable to the elongation conditions but readily cleaved later. Examples of which are: oxime resin (DeGrado and Kaiser (1980) J. Org. Chem. 45, 1295-1300) chloro or bromomethyl resin, hydroxymethyl resin, and aminomethyl resin. Many of these resins are commercially available with the desired C-terminal amino acid already incorporated .
  • acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl
  • aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyIs , 1- (p-biphenyl) -1-methylethoxycarbonyl , and 9-fluorenylmethyloxycarbonyl (Fmoc)
  • 3) aliphatic carbamate types such as tert-butyloxycarbonyl (Boc) , ethoxycarbonyl, diisopropylmethoxycarbonyl , and allyloxycarbonyl
  • cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl
  • 5) alkyl types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl
  • alkyl types such as cycl
  • the preferred ⁇ -amino protecting group is either Boc or Fmoc. Many amino acid derivatives suitably protected for peptide synthesis are commercially available. The ⁇ -amino protecting group is cleaved prior to the coupling of the next amino acid.
  • Boc group the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HC1 in dioxane.
  • the resulting ammonium salt is then neutralized either prior to the coupling or in situ with basic solutions such as aqueous buffers, or tertiary amines in dichloromethane or dimethylformamide.
  • the reagents of choice are piperidine or substituted piperidines in dimethylformamide, but any secondary amine or aqueous basic solutions can be used.
  • the deprotection is carried out at a temperature between 0 °C and room temperature. Any of the amino acids bearing side chain functionalities may be protected during the preparation of the peptide using any of the above-identified groups. Those skilled in the art will appreciate that the selection and use of appropriate protecting groups for these side chain functionalities will depend upon the amino acid and presence of other protecting groups in the peptide. The selection of such a protecting group is important in that it must not be removed during the deprotection and coupling of the ⁇ -amino group .
  • Boc when Boc is chosen for the ⁇ -amine protection the following protecting groups are acceptable: p-toluenesulfonyl (tosyl) moieties and nitro for arginine; benzyloxycarbonyl , substituted benzyloxycarbonyls, tosyl or trifluoroacetyl for lysine; benzyl or alkyl esters such as cyclopentyl for glutamic and aspartic acids; benzyl ethers for serine and threonine; benzyl ethers, substituted benzyl ethers or 2-bromobenzyloxycarbonyl for tyrosine; p- methylbenzyl , p-methoxybenzyl, acetamidomethyl, benzyl, or t-butylsulfonyl for cysteine; and the indole of tryptophan can either be left unprotected or protected with a formyl group
  • tert-butyl based protecting groups are acceptable .
  • Boc can be used for lysine, tert-butyl ether for serine, threonine and tyrosine, and tert-butyl ester for glutamic and aspartic acids.
  • the peptide When a solid phase synthesis is used, the peptide should be removed from the resin without simultaneously removing protecting groups from functional groups that might interfere with the cyclization process. Thus, if the peptide is to be cyclized in solution, the cleavage conditions need to be chosen such that a free ⁇ -carboxylate and a free ⁇ -amino group are generated without simultaneously removing other protecting groups. Alternatively, the peptide may be removed from the resin by hydrazinolysis, and then coupled by the azide method.
  • Another very convenient method involves the synthesis of peptides on an oxime resin, followed by intramolecular nucleophilic displacement from the resin, which generates a peptide (Osapay, Profit, and Taylor (1990) Tetrahedron Letters 43, 6121-6124) .
  • the oxime resin is employed, the Boc protection scheme is generally chosen.
  • the preferred method for removing side chain protecting groups generally involves treatment with anhydrous HF containing additives such as dimethyl sulfide, anisole, thioanisole, or p-cresol at 0 °C.
  • the cleavage of the peptide can also be accomplished by other acid reagents such as trifluoromethanesulfonic acid/trifluoroacetic acid mixtures.
  • Unusual amino acids used in this invention can be synthesized by standard methods familiar to those skilled in the art ("The Peptides: Analysis, Sythesis, Biology, Vol. 5, pp. 342-449, Academic Press, New York (1981)). N-Alkyl amino acids can be prepared using procedures described in previously (Cheung et al . , (1977) Can . J. Chem . 55, 906; Freidinger et al . , (1982) J. Org . Chem . 48, 77 (1982)), which are incorporated here by reference.
  • the compounds of the present invention may be prepared using the procedures further detailed below. Representative materials and methods that may be used in preparing the compounds of the invention are described further below.
  • HBTU 2-(lH- Benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate
  • N-methylmorpholine (NMM) , m-cresol , D- 2-aminobutyric acid (Abu) , trimethylacetylchloride, diisopropylethylamine (DIEA) were purchased from Aldrich Chemical Company.
  • Dimethylformamide (DMF) , ethyl acetate, chloroform (CHCI3), methanol (MeOH) , pyridine and hydrochloric acid (HCl) were obtained from Baker.
  • the reaction mixture was stirred at 0°C for 24 hr.
  • the solvent was removed by rotary evaporation to yield an oil, which was dissolved in 25 mL of EtOAc and washed with H 2 0, 5% citric acid, sat. NaHC ⁇ 3 , brine and dried over MgS ⁇ 4 .
  • the Boc group on B was removed by stirring with 5 mL of TFA and 5 mL of CH 2 C1 2 .
  • the reaction mixture was stired for 2 hr and then the solvent removed under vacuum. Subsequently, 3 washes of CH 2 C1 was performed to remove traces of TFA.
  • Coupling of the guanidino benzoic acid was achieved by mixing 0.8g, 1.25 mmoles of B with 0.285g, 1.32 mmoles of guanidino benzoic acid in the presence of 0.424g, 1.32 mmoles of TBTU, 740 mL, 4.25 mmoles of DIPEA in 15 L of DMF.
  • the reaction mixture was stirred overnite at 0°C before work-up to yield the protected functionalized chelator as an oil. Removal of the protecting groups (OBzl and Z) was achieved by dissolving 60 mg of C in 1-2 mL of TFA.
  • the reaction mixture was cooled to -16°C in a acetone/dry ice bath.
  • TFMSA 1-2 mL was added dropwise while maintaining the temp. about -10°C C.
  • 0.4 mL of anisole was added and the reaction mixture which turned purple was stirred at -10°C for an additional 3 hr.
  • 45 mL of cold diethyl ether was added to the reaction mixture and the temperature was lowered to about -35 C.
  • the mixture was stirred under these conditions for 0.5 hr, upon which the temperature was further lowered to about -78°C and stirred for another 1.5 hr .
  • the white precipitate formed was filtered through a medium fritted funnel and washed several times with cold ether.
  • the precipitate was transferred to a 100 mL flask and dissolved in 20 mL of a water : acetone (1:1) mixture. This solution was treated with 1.5 mL of Bio-Rad- AG 1x2 (acetate) prewashed resin. The mixture was stirred for 30 minutes upon which the pH changed from 1.0 to 4.5. The soution was filtered, the resin washed (3 x 5 L) with water and the filtrate lyophilized.
  • Example 2 was achieved by a procedure similar to that used in Example 1, except that Boc- ⁇ -Ala instead of Z-Dap (Boc) -OH was used to prepare the chelator backbone .
  • Example 3 Preparation of 3- ( (acetylamino)methylthio) -2- (2- (3- ( (4- ( ( amidinoamino ) methyl ) phenyl ) carbonylamino ) -2 - aminopropanoylamino) acetylamino)propanoic acid
  • Example 3a 3- ( (acetylamino)methylthio) -2-(2-(3-((4- ( (amidinoamino) methyl) phenyl) carbonylamino) -2- aminopropanoylamino) -3 -carboxypropanoylamino)propanoic acid
  • Example 3b 3- ( (acetylamino)methylthio) -2- (2- (3- ( (4- (amidinoamino) phenyl) carbonylamino) -2 -aminopropanoylamino) - 3-carboxypropanoylamino)propanoic acid
  • Examples 3a-d was achieved by manual solid phase peptide synthesis using fmoc-teabag chemistry on a wang resin solid support.
  • the 5.0 x 5.0 cm teabags were made from 0.75 mm mesh polypropylene filters (Spectra Filters) and filled with 0.5 g of the commercially available S-acetamidomethyl-L-cysteine on Wang resin.
  • synthesis of the protected tri-peptide resin intermediate was achieved using sequential coupling of the respective fmoc-amino acids and guanidinomethyl- or guanidinobenzoic acid to the S-acetamidomethyl-L-cysteine on Wang resin.
  • Ret. Time (min) Example 3a: 8.55; Example 3b: 9.01; Example 3c: 8.33; Example 3d: 11.06.
  • Example 3a MS-FAB m/z calcd. for C 2 oH 30 N 8 0 6 S+H: 511.6; Found: 511.2.
  • Example 3b MS-FAB m/z calcd. for C 22 H 32 N 8 0 8 S+H: 569.6; Found: 569.2.
  • Example 3c MS-FAB m/z calcd. for C 2 ⁇ H 30 N 8 O 8 S+H: 555.6; Found: 555.3.
  • Example 3d MS-FAB m/z calcd. for C 2 ⁇ H 29 N 7 0 8 S+H: 540.6; Found: 540.2.
  • Example 3c Preparation of the Tc-99m complex of Example 3c A solution of the Example 3c was prepared by dissolving 0.2 mg in 0.5 mL of 20 mM phosphate buffer (pH 11) . To this solution was added 0.2 mL of 99 ⁇ n Tc ⁇ 4 ⁇ (30 mCi). To this was added a 0.2 mL of a sat. stannous tartarate solution and the reaction mixture heated at 80°C for 30 min followed by cooling at RT. After cooling about 2 minutes, 20 ⁇ L of the solution was analyzed by the HPLC method described below:
  • the radiochemical purity (% RCP) of the resulting complex was determined using HPLC.
  • the method used a Hewlett Packard 1050 instrument and a Vydac C18 column (4.6 mm x 25 cm) at a flow rate of 1 mL/min with a gradient mobile phase from 100% A (10 mM phosphate buffer, pH 6.0), to 7% B (acetonitrile) at 15 min and 80% B at 25 min.
  • Tc-99m complex of Example 3c A solution of the Example 3c was prepared by dissolving 0.2 mg in 0.25 mL of 20 mM phosphate buffer (pH 11) . To this solution was added 1.0 mL of decayed Tc-99m generator eluate and 0.15 mL of a sat. stannous tartarate solution. The reaction mixture was heated at 80°C for 30 min followed by cooling at RT. After cooling about 2 minutes, 20 ⁇ L of the solution was analyzed by the HPLC method described in example 4. For comparison the Tc-99m complex as described in example 4 was also simultaneously prepared and analyzed by HPLC.
  • the radio chromatograms of the Tc-99m and the Tc- 99 complexes had similar retention times indicating the formation of similar species at both the "tracer” and the macroscopic level.
  • Three batches of the Tc-99m complex of Example 3c were evaluated in the GPIIb/IIIa binding assay using hPRP and found to have at least preferred IC 50 ( ⁇ M) values .
  • the radiolabeled compounds of the present invention are useful as radiopharmaceuticals for imaging a thrombus such as may be present in a patient with unstable angina, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, diabetes, thrombophlebitis, pulmonary emboli, or prosthetic cardiac devices such as heart valves, and thus may be used to diagnose such present or potential disorders.
  • the patient may be any type of a mammal, but is preferably a human.
  • the radiolabeled compounds may be used alone, or may be employed as a composition with a radiopharmaceutically acceptable carrier, and/or in combination with other diagnostic or therapeutic agents.
  • radiopharmaceuticals carriers and suitable amounts thereof are well known in the art, and can be found in, for example, Remington's Pharmaceutical Sciences, Gennaro, A.R., ed. , Mack Publishing Company, Easton, PA (1985), and The United States Pharmacopia-The National Formulary, 22nd
  • kits containing the compounds of the present invention.
  • kits may contain the compounds in sterile lyophilized form, and may include a sterile container of a radiopharmaceutically acceptable reconstitution liquid. Suitable reconstitution liquids are disclosed in Remington's Pharmaceutical Sciences and The United States Pharmacopia- The National Formulary, cited above.
  • kits may alternatively contain a sterile container of a composition of the radiolabeled compounds of the invention.
  • kits may also include, if desired, other conventional kit components, such as, for example, one or more carriers, or one or more additional vials for mixing.
  • kits for indicating quantities of the labeled compounds of the invention and carrier, guidelines for mixing these components, and protocols for administration may also be included in the kit.
  • Sterilization of the containers and any materials included in the kit and lyophilization (also referred to as freeze- drying) of the labeled compounds of the invention may be carried out using conventional sterilization and lyophilization methodologies known to those skilled in the art .
  • Diagnostic kits of the present invention comprise one or more vials containing the sterile, non-pyrogenic, formulation comprised of a predetermined amount of a compound of formula (I) , a reducing agent, and optionally a solubilization aid or other components such as transfer ligands, buffers, lyophilization aids, stabilization aids, and bacteriostats .
  • a solubilization aid or other components such as transfer ligands, buffers, lyophilization aids, stabilization aids, and bacteriostats .
  • the inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practising end user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical.
  • the improvement achieved by the inclusion of an optional component in the formulation must be weighed against the added complexity of the formulation and added cost to manufacture the kit.
  • the one or more vials that contain all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid.
  • Solubilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to ethanol, glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monoloeate, polysorbates, poly (oxyethylene) poly (oxypropylene) oly (oxyethylene) block copolymers (Pluronics) and lecithin.
  • Preferred solubilizing aids are polyethylene glycol, and Pluronics.
  • Buffers useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to phosphate, citrate, sulfosalicylate, and acetate. A more complete list can be found in the United States Pharmacopeia . Lyophilization aids useful in the preparation of diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to mannitol, lactose, sorbitol, dextran, Ficoll, and polyvinylpyrrolidine (PVP) .
  • PVP polyvinylpyrrolidine
  • Stabilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of the same include but are not limited to ascorbic acid, cysteine, monothioglycerol, sodium bisulfite, sodium metabisulfite, gentisic acid, and inositol .
  • Bacteriostats useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to benzyl alcohol, benzalkonium chloride, chlorbutanol, and methyl, propyl or butyl paraben.
  • a component in a diagnostic kit can also serve more than one function.
  • a reducing agent can also serve as a stabilization aid
  • a buffer can also serve as a transfer ligand
  • a lyophilization aid can also serve as a transfer, ancillary or co-ligand and so forth.
  • the predetermined amounts of each component in the formulation are determined by a variety of considerations that are in some cases specific for that component and in other cases dependent on the amount of another component or the presence and amount of an optional component . In general, the minimal amount of each component is used that will give the desired effect of the formulation.
  • the desired effect of the formulation is that the practising end user can synthesize the radiopharmaceutical and have a high degree of certainty that the radiopharmaceutical can be safely injected into a patient and will provide diagnostic information about the disease state of that patient.
  • the diagnostic kits of the present invention may also contain written instructions for the practising end user to follow to synthesize the radiopharmaceuticals . These instructions may be affixed to one or more of the vials or to the container in which the vial or vials are packaged for shipping or may be a separate insert, termed the package insert.
  • the radiolabeled compounds are generally administered intravenously, by bolus injection, although they may be administered by any means that produces contact of the compounds with platelets. Suitable amounts for administration will be readily ascertainable to those skilled in the art, once armed with the present disclosure.
  • the dosage administered will, of course, vary depending up such known factors as the particular compound administered, the age, health and weight or the nature and extent of any symptoms experienced by the patient, the amount of radiolabeling, the particular radionuclide used as the label, the rate of clearance of the radiolabeled compounds from the blood.
  • a dosage range of the radiolabeled compounds of the invention may be between about 1 and about 40 mCi .
  • the presence of thrombi may be visualized using a standard radioscintographic imaging system, such as, for example, a gamma camera or a computed tomographic device.
  • a standard radioscintographic imaging system such as, for example, a gamma camera or a computed tomographic device.
  • imaging systems are well known in the art, and are discussed, for example, in Macovski, A., Medical Imaging Systems, Information and Systems Science Series, Kailath, T., ed., Prentice-Hall, Inc., Englewood Cliffs, NJ (1983).
  • Particularly preferred are single-photon emission computed tomography (SPECT) and positron emission tomography (PET) .
  • SPECT single-photon emission computed tomography
  • PET positron emission tomography
  • imaging is carried out by scanning the entire patient, or a particular region of the patient suspected of having a thrombus formation, using the radioscintographic system, and detecting the radioisotope signal. The detected signal is then converted into an image of the thrombus by the system. The resultant images should be read by an experienced observer, such as, for example, a nuclear medicine physician.
  • imaging is referred to herein as "imaging" the patient.
  • imaging is carried out about 1 minute to about 48 hours following administration of the radiolabeled compound of the invention. The precise timing of the imaging will be dependant upon such factors as the half-life of the radioisotope employed, and the clearance rate of the compound administered, as will be readily apparent to those skilled in the art.
  • imaging is carried out between about 1 minute and about 4 hours following administration .
  • radiolabeled compounds of the invention which have the ability to localize specifically and with high affinity in thrombi, to detect the presence of thrombi and/or to diagnose thromboembolic disorders in a patient, will be readily apparent to those skilled in the art, once armed with the present disclosure.
  • Human PRP h-PRP
  • h-PRP Human PRP
  • Aliquots of platelets (5 X 10 ⁇ cells) along with 1 mM calcium chloride were added to removable 96 well plates prior to the activation of the human gel purified platelets (h-GPP) .
  • Activation of the human gel purified platelets was achieved using ADP, collagen, arachidonate, epinephrine, and/or thrombin in the presence of the ligand, 125 _fibrinogen.
  • the 12 5 _fibrinogen bound to the activated, platelets was separated from the free form by centrifugation and then counted on a gamma counter.
  • the test compounds were added at various concentrations prior to the activation of the platelets .
  • Preferred compounds of the present invention would include those compounds having an IC 50 value of less than about 1 mM, more preferably an IC 50 value of less than about 0.1 mM, even more preferably an IC 50 value of less than about 0.01 mM, still more preferably an IC 50 value of less than about 0.001 mM, and most preferably an IC 50 value of about 0.0005 mM.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux composés correspondant à la formule (I) dans laquelle R?1, R2, R3, R4¿ et n sont définis dans la description, qui fonctionnent comme antagonistes du complexe de glycoprotéine plaquettaire IIb/IIIa, des produits radiopharmaceutiques étiquetés 99mTc préparés à partir de ces composés, des procédés de leur utilisation comme agents d'imagerie dans le diagnostic de thrombus artériels et veineux ainsi que des kits comprenant ces composants.
PCT/US1999/023511 1998-10-13 1999-10-13 Utilisation de desintegrines synthetiques mimetiques arg-gly-asp (rgd) incorporees dans un chelateur comme agents d'imagerie WO2000021980A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002341672A CA2341672A1 (fr) 1998-10-13 1999-10-13 Utilisation de desintegrines synthetiques mimetiques arg-gly-asp (rgd) incorporees dans un chelateur comme agents d'imagerie
JP2000575885A JP2002527450A (ja) 1998-10-13 1999-10-13 画像形成試薬としてのキレーターが組み込まれたＡｒｇ−Ｇｌｙ−Ａｓｐ（ＲＧＤ）ミメティック合成ディスインテグリン類
AU64222/99A AU6422299A (en) 1998-10-13 1999-10-13 Chelator incorporated arg-gly-asp (rgd) mimetic synthetic disintegrins as imaging agents
EP99951874A EP1121377A1 (fr) 1998-10-13 1999-10-13 Utilisation de desintegrines synthetiques mimetiques arg-gly-asp (rgd) incorporees dans un chelateur comme agents d'imagerie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10392598P 1998-10-13 1998-10-13
US60/103,925 1998-10-13

Publications (1)

Publication Number Publication Date
WO2000021980A1 true WO2000021980A1 (fr) 2000-04-20

Family

ID=22297740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023511 WO2000021980A1 (fr) 1998-10-13 1999-10-13 Utilisation de desintegrines synthetiques mimetiques arg-gly-asp (rgd) incorporees dans un chelateur comme agents d'imagerie

Country Status (5)

Country Link
EP (1) EP1121377A1 (fr)
JP (1) JP2002527450A (fr)
AU (1) AU6422299A (fr)
CA (1) CA2341672A1 (fr)
WO (1) WO2000021980A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107794A2 (fr) * 2005-04-01 2006-10-12 The Board Of Regents Of The University Of Texas System Chelateur poly(peptide): procedes de fabrication et d'utilisation
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US9770520B2 (en) 2010-12-20 2017-09-26 Guerbet Chelate nanoemulsion for MRI

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015818A1 (fr) * 1989-06-19 1990-12-27 Antisoma Limited Peptides synthetiques destines a la detection des thrombus
WO1994009036A1 (fr) * 1992-10-19 1994-04-28 Temple University Of The Commonwealth System Of Higher Education Detection d'un thrombus a l'aide de desintegrines radiomarquees
WO1994022494A1 (fr) * 1993-03-30 1994-10-13 The Du Pont Merck Pharmaceutical Company ANTAGONISTES RADIOMARQUES DES RECEPTEURS PLAQUETTAIRES GPIIb/IIIa, UTILISES COMME AGENTS DE VISUALISATION POUR LE DIAGNOSTIC DES AFFECTIONS THROMBOEMBOLIQUES
WO1998014220A2 (fr) * 1996-10-02 1998-04-09 Du Pont Pharmaceuticals Company PEPTIDES CYCLIQUES CONTENANT DES AGENTS CHELATANTS ET MARQUES AU TECHNETIUM 99 m

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015818A1 (fr) * 1989-06-19 1990-12-27 Antisoma Limited Peptides synthetiques destines a la detection des thrombus
WO1994009036A1 (fr) * 1992-10-19 1994-04-28 Temple University Of The Commonwealth System Of Higher Education Detection d'un thrombus a l'aide de desintegrines radiomarquees
WO1994022494A1 (fr) * 1993-03-30 1994-10-13 The Du Pont Merck Pharmaceutical Company ANTAGONISTES RADIOMARQUES DES RECEPTEURS PLAQUETTAIRES GPIIb/IIIa, UTILISES COMME AGENTS DE VISUALISATION POUR LE DIAGNOSTIC DES AFFECTIONS THROMBOEMBOLIQUES
WO1998014220A2 (fr) * 1996-10-02 1998-04-09 Du Pont Pharmaceuticals Company PEPTIDES CYCLIQUES CONTENANT DES AGENTS CHELATANTS ET MARQUES AU TECHNETIUM 99 m

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107794A2 (fr) * 2005-04-01 2006-10-12 The Board Of Regents Of The University Of Texas System Chelateur poly(peptide): procedes de fabrication et d'utilisation
WO2006107794A3 (fr) * 2005-04-01 2007-09-20 Univ Texas Chelateur poly(peptide): procedes de fabrication et d'utilisation
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US9770520B2 (en) 2010-12-20 2017-09-26 Guerbet Chelate nanoemulsion for MRI

Also Published As

Publication number Publication date
JP2002527450A (ja) 2002-08-27
AU6422299A (en) 2000-05-01
EP1121377A1 (fr) 2001-08-08
CA2341672A1 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
EP0692982B1 (fr) ANTAGONISTES RADIOMARQUES DES RECEPTEURS PLAQUETTAIRES GPIIb/IIIa, UTILISES COMME AGENTS DE VISUALISATION POUR LE DIAGNOSTIC DES AFFECTIONS THROMBOEMBOLIQUES
EP0832068B1 (fr) Reactifs stables destines a la preparation de produits radiopharmaceutiques
JP5237283B2 (ja) インテグリンのためのイメージング剤としてのシクロペプチド誘導体
KR100932827B1 (ko) 펩티드계 화합물
ES2241313T3 (es) Compuestos farmaceuticos para la formacion de imagenes de trastornos angiogenicos.
US6565828B2 (en) Macrocyclic chelants for metallopharmaceuticals
CN100509061C (zh) 改进的螯合剂缀合物
WO2008033557A2 (fr) Peptidomimétiques cycliques dérivés de la chimie clic et utilisés en tant que marqueurs d'intégrine
AU2007201609A1 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
AU727656B2 (en) Technetium-99m labeled chelator incorporated cyclic peptides
EP1268497B1 (fr) Complexes avec de ligand ternaire utiles en tant que produits radiopharmaceutiques
US6517814B2 (en) Macrocyclic chelants useful for metallopharmaceuticals
EP2182974B1 (fr) Azapeptides cycliques en tant que marqueurs d'intégrine
US6524554B1 (en) Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
EP1121377A1 (fr) Utilisation de desintegrines synthetiques mimetiques arg-gly-asp (rgd) incorporees dans un chelateur comme agents d'imagerie
US6685914B1 (en) Macrocyclic chelants for metallopharmaceuticals
US20030152512A1 (en) Imaging thrombus with glycoprotein llb/llla antagonists
US6251364B1 (en) Ternary ligand complexes useful as radiopharmaceuticals
US6818659B2 (en) (2S)-2-amino-4-(2-amino-(3,4,5,6-tetrahydropyrimidin-4-yl) butanoyl and its use in cyclic and acyclic peptides
MXPA00009574A (en) Pharmaceuticals for the imaging of angiogenic disorders

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64222

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BR CA CN CZ EE HU IL IN JP KR LT LV MK MX NO NZ PL SG SI SK TR UA US VN ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2341672

Country of ref document: CA

Ref country code: CA

Ref document number: 2341672

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999951874

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 575885

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999951874

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999951874

Country of ref document: EP